Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGM | P11217 | 3/20 | 0.57 |
| ▸ | CDK1 | P06493 | 1/20 | 0.52 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.51 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.51 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.51 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.51 |
| ▸ | TK2 | O00142 | 4/20 | 0.50 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.49 |
| ▸ | TYMP | P19971 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18871260 | 1.00 | PYGM (0.57) | PYGMCDK1SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL28817 | 1.00 | PYGM (0.57) | PYGMCDK1SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL29754 | 1.00 | PYGM (0.57) | PYGMCDK1SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL15810706 | 1.00 | PYGM (0.57) | PYGMCDK1SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL2903546 | 1.00 | PYGM (0.57) | PYGMCDK1SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL17210997 | 1.00 | PYGM (0.57) | PYGMCDK1SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL5091966 | 0.90 | TK2 (0.47) | PYGMCDK1TK2TYMP | |
| SCHEMBL20830476 | 0.90 | PYGM (0.45) | PYGMCDK1TK2P2RY2 | |
| SCHEMBL12642176 | 0.89 | CDA (0.48) | PYGMCDK1TK2TYMP | |
| SCHEMBL22460365 | 0.89 | CDA (0.48) | PYGMCDK1TK2TYMP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 4987 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4705468-A1 | MAMMALIAN POLYCISTRONIC EXPRESSION SYSTEM FOR DIRECT TRANSLATION FROM RNA AND SECRETION OF CARGO | California Institute of Technology (US) | 2026-03-11 | — | — | EP | claimed |
| EP-4705481-A2 | CIRCULAR RNA COMPOSITIONS AND METHODS | Orna Therapeutics, Inc. (US) | 2026-03-11 | — | — | EP | claimed |
| EP-4632075-A2 | METHOD FOR REDUCING IMMUNOGENICITY OF RNA | BioNTech SE (DE) | 2025-10-15 | — | — | EP | claimed |
| US-20250304965-A1 | DOUBLE-STRANDED RNA MOLECULE AND PHARMACEUTICAL USE THEREOF | MACAU UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2025-10-02 | — | — | US | claimed |
| EP-4029522-B1 | METHOD FOR REDUCING IMMUNOGENICITY OF RNA | BioNTech SE (DE) | 2025-08-13 | — | — | EP | claimed |
| WO-2025129186-A1 | CLOSTRIDIOIDES DIFFICILE VACCINE AND METHODS OF USE | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2025-06-19 | — | — | WO | claimed |
| US-20250161488-A1 | THERAPEUTIC mRNA | THE UNIVERSITY OF MELBOURNE (AU) | 2025-05-22 | — | — | US | claimed |
| US-20250019719-A1 | Purification and Purity Assessment of RNA Molecules Synthesized with Modified Nucleosides | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2025-01-16 | — | — | US | claimed |
| CN-117866948-B | Negative selection method and system for purifying circular nucleic acid | 上海环码生物医药有限公司 | 2024-12-13 | — | — | CN | claimed |
| WO-2024233308-A2 | CIRCULAR RNA COMPOSITIONS AND METHODS | ORNA THERAPEUTICS, INC. (US) | 2024-11-14 | — | — | WO | claimed |
| US-20070231810-A1 | Multicomponent nucleic acid enzymes and methods for their use | SPEEDX PTY LTD (AU) | 2007-10-04 | — | — | US | claimed |
| WO-2007041774-A1 | MULTICOMPONENT NUCLEIC ACID ENZYMES AND METHODS FOR THEIR USE | JOHNSON & JOHNSON RESEARCH PTY LIMITED (AU) | 2007-04-19 | — | — | WO | claimed |
| US-6727278-B1 | PYRIMETHAMIN, CROMOLYN SODIUM, ERYTHYROMYCIN, PURPUROGALLIN, TARTRAZINE, SULFANILAMIDE, BENZOPURPURINE, PHTHALOCYANINE, 5-METHYL-2-THIOURIDINE AND 1,2-BENZYLSOXAZOLE CROSSES BLOOD-BRAIN BARRIER; ALZHEIMER*S DISEASE | DMS PHARMACEUTICAL INC. (CA) | 2004-04-27 | — | — | US | claimed |
| US-6706691-B1 | BIOAVAILABILITY OF COMPOSITIONS METABOLIZED BY THE GUT P450 ISOZYMES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2004-03-16 | — | — | US | claimed |
| US-20030007961-A1 | Orthomolecular vitamin E derivatives | WILBURN MICHAEL D (US) | 2003-01-09 | — | — | US | claimed |
| EP-0795029-A1 | CHEMICAL LABELLING OF OBJECTS | Pabio (NO) | 1997-09-17 | — | — | EP | claimed |
| US-5567720-A | ALZHEIMER'S DISEASE | DMS PHARMACEUTICAL INC. (CA) | 1996-10-22 | — | — | US | claimed |
| WO-1996017954-A1 | CHEMICAL LABELLING OF OBJECTS | PABIO (DK) | 1996-06-13 | — | — | WO | claimed |
| EP-0460078-A1 | PHARMACEUTICALLY ACTIVE AGENTS THAT IMPEDE AMYLOID FORMATION IN VIVO | AVERBACK, Paul (CA) | 1991-12-11 | — | — | EP | claimed |
| WO-1990009789-A2 | PHARMACEUTICALLY ACTIVE AGENTS THAT IMPEDE AMYLOID FORMATION IN VIVO | AVERBACK PAUL (CA) | 1990-09-07 | — | — | WO | claimed |